Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
NEWTON, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 428,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma
-- Selinexor Marketing Authorization Application to be Reviewed Under Accelerated Assessment -- NEWTON, Mass. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing Authorization
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 78,000 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7,
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 180,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
-- Oral Selinexor Achieves 26.2% Overall Response Rate in STORM Study, 4.4 Month Median Duration of Response, 8.6 Month Median Overall Survival and 15.6 Month Median Survival in Patients with MR or Better -- -- Once Weekly Oral Selinexor in Combination with Darzalex ® and Low Dose Dexamethasone
View HTML
Toggle Summary Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
-- 29.6% Overall Response Rate Including 9.6% Complete Response Rate -- -- Amongst the Patients with Complete or Partial Response, Median Duration of Response was 9.2 Months and Median Overall Survival was 29.7 months -- -- Company Plans to Submit New Drug Application to the FDA in the First Half
View HTML
Toggle Summary Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
-- U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review; Assigns PDUFA Action Date of April 6, 2019 -- -- Fast Track Designation Received for Selinexor in Relapsed or Refractory DLBCL; Top-Line Phase 2b SADAL Data in DLBCL Selected for
View HTML
Toggle Summary Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
NEWTON, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound
View HTML